0.00Open0.05Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-59.41%PremiumSep 20, 2024Expiry Date7.44Intrinsic Value100Multiplier35DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma248.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cidara Therapeutics Stock Discussion
Dow Jones· 1 min ago
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$Cidara Therapeutics (CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
No comment yet